Literature DB >> 22480925

Potential overestimation of HPV vaccine impact due to unmasking of non-vaccine types: quantification using a multi-type mathematical model.

Yoon Hong Choi1, Ruth Chapman, Nigel Gay, Mark Jit.   

Abstract

INTRODUCTION: Estimates of human papillomavirus (HPV) vaccine impact in clinical trials and modelling studies rely on DNA tests of cytology or biopsy specimens to determine the HPV type responsible for a cervical lesion. DNA of several oncogenic HPV types may be detectable in a specimen. However, only one type may be responsible for a particular cervical lesion. Misattribution of the causal HPV type for a particular abnormality may give rise to an apparent increase in disease due to non-vaccine HPV types following vaccination ("unmasking").
METHODS: To investigate the existence and magnitude of unmasking, we analysed data from residual cytology and biopsy specimens in English women aged 20-64 years old using a stochastic type-specific individual-based model of HPV infection, progression and disease. The model parameters were calibrated to data on the prevalence of HPV DNA and cytological lesion of different grades, and used to assign causal HPV types to cervical lesions. The difference between the prevalence of all disease due to non-vaccine HPV types, and disease due to non-vaccine HPV types in the absence of vaccine HPV types, was then estimated.
RESULTS: There could be an apparent maximum increase of 3-10% in long-term cervical cancer incidence due to non-vaccine HPV types following vaccination.
CONCLUSION: Unmasking may be an important phenomenon in HPV post-vaccination epidemiology, in the same way that has been observed following pneumococcal conjugate vaccination.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22480925     DOI: 10.1016/j.vaccine.2012.03.065

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

1.  Seven challenges for model-driven data collection in experimental and observational studies.

Authors:  J Lessler; W J Edmunds; M E Halloran; T D Hollingsworth; A L Lloyd
Journal:  Epidemics       Date:  2014-12-16       Impact factor: 4.396

2.  Time trend analysis of cervical high-risk human papillomavirus (HPV) in HIV-infected women in an urban cohort from Rio de Janeiro, Brazil: the rise of non-16/18 HPV.

Authors:  Mary C Cambou; José Eduardo Levi; Jordan E Lake; Angela de Andrade; Emilia M Jalil; Fabio Russomano; Mônica Derrico; Valdilea G Veloso; Ruth K Friedman; Paula M Luz; Beatriz Grinsztejn
Journal:  Int J Infect Dis       Date:  2015-10-28       Impact factor: 3.623

3.  Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial.

Authors:  Jaimie Z Shing; Shangying Hu; Rolando Herrero; Allan Hildesheim; Carolina Porras; Joshua N Sampson; John Schussler; John T Schiller; Douglas R Lowy; Mónica S Sierra; Loretto Carvajal; Aimée R Kreimer
Journal:  Lancet Oncol       Date:  2022-06-13       Impact factor: 54.433

Review 4.  Update on prevention and screening of cervical cancer.

Authors:  Shaniqua L McGraw; Jeanne M Ferrante
Journal:  World J Clin Oncol       Date:  2014-10-10

5.  Impact of vaccination on 14 high-risk HPV type infections: a mathematical modelling approach.

Authors:  Simopekka Vänskä; Kari Auranen; Tuija Leino; Heini Salo; Pekka Nieminen; Terhi Kilpi; Petri Tiihonen; Dan Apter; Matti Lehtinen
Journal:  PLoS One       Date:  2013-08-29       Impact factor: 3.240

6.  Reducing Poverty-Related Disparities in Cervical Cancer: The Role of HPV Vaccination.

Authors:  Jennifer C Spencer; Noel T Brewer; Tamera Coyne-Beasley; Justin G Trogdon; Morris Weinberger; Stephanie B Wheeler
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-09-09       Impact factor: 4.254

Review 7.  Are the currently existing anti-human papillomavirus vaccines appropriate for the developing world?

Authors:  Lj van Bogaert
Journal:  Ann Med Health Sci Res       Date:  2013-07

8.  Comparing human papillomavirus prevalences in women with normal cytology or invasive cervical cancer to rank genotypes according to their oncogenic potential: a meta-analysis of observational studies.

Authors:  Erik Bernard; Margarita Pons-Salort; Michel Favre; Isabelle Heard; Elisabeth Delarocque-Astagneau; Didier Guillemot; Anne C M Thiébaut
Journal:  BMC Infect Dis       Date:  2013-08-13       Impact factor: 3.090

9.  HPV vaccination programs have not been shown to be cost-effective in countries with comprehensive Pap screening and surgery.

Authors:  Judy Wilyman
Journal:  Infect Agent Cancer       Date:  2013-06-12       Impact factor: 2.965

10.  Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy.

Authors:  Francesca Carozzi; Donella Puliti; Cristina Ocello; Pasquale Silvio Anastasio; Espedito Antonio Moliterni; Emilia Perinetti; Laurence Serradell; Elena Burroni; Massimo Confortini; Paola Mantellini; Marco Zappa; Géraldine Dominiak-Felden
Journal:  BMC Infect Dis       Date:  2018-01-15       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.